Moran Y Nunberg1,2, Lael Werner1,2, Uri Kopylov2,3, Yael Haberman1,2, Avishay Lahad1,2, Batia Weiss1,2, Dror S Shouval1,2. 1. Pediatric Gastroenterology Unit, Edmond and Lily Safra Children's Hospital, Tel Hashomer. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv. 3. Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Israel.
Abstract
OBJECTIVES: Interleukin-10 (IL-10) is an immunoregulatory cytokine that has a central role in suppressing proinflammatory responses. Patients with deleterious mutations in interleukin (IL)-10 or IL-10 receptor (IL-10R) genes develop severe colitis and perianal disease in the first months of life. Whether IL-10R expression and signaling in pediatric- or adult-onset Crohn disease (CD) are altered is unknown. The objective of this study was to characterize IL-10R expression and IL-10R-mediated suppression in patients with CD. METHODS: Monocytes were sorted from peripheral blood mononuclear cells of patients with CD and control subjects. IL-10R expression was determined by flow cytometry. Monocytes were stimulated with lipopolysaccharide (LPS) for 3 hours in the presence of different concentrations of IL-10 to determine IL-10-mediated suppression of tumor necrosis factor α production. Signaling through the IL-10R was evaluated by quantifying STAT3 phosphorylation in response to IL-10 stimulation. RESULTS: Forty-two subjects were enrolled in this study: 19 with CD and 23 controls. Stimulation of monocytes with LPS markedly increased IL-10R expression in both groups but to a much lower extent in patients with CD. In addition, IL-10-mediated suppression of TNFα production upon LPS stimulation and IL-10-induced STAT3 phosphorylation were attenuated in patients with CD versus controls. Finally, LPS-stimulated monocytes from patients with CD secreted significantly lower quantities of IL-10, compared with control monocytes. CONCLUSIONS: IL-10R expression and signaling are decreased in monocytes from patients with CD. Additional studies are required to assess whether similar patterns occur in other innate immune cells, especially in the gut, and whether disease activity, medical therapy, and genetic factors modulate these findings.
OBJECTIVES:Interleukin-10 (IL-10) is an immunoregulatory cytokine that has a central role in suppressing proinflammatory responses. Patients with deleterious mutations in interleukin (IL)-10 or IL-10 receptor (IL-10R) genes develop severe colitis and perianal disease in the first months of life. Whether IL-10R expression and signaling in pediatric- or adult-onset Crohn disease (CD) are altered is unknown. The objective of this study was to characterize IL-10R expression and IL-10R-mediated suppression in patients with CD. METHODS: Monocytes were sorted from peripheral blood mononuclear cells of patients with CD and control subjects. IL-10R expression was determined by flow cytometry. Monocytes were stimulated with lipopolysaccharide (LPS) for 3 hours in the presence of different concentrations of IL-10 to determine IL-10-mediated suppression of tumor necrosis factor α production. Signaling through the IL-10R was evaluated by quantifying STAT3 phosphorylation in response to IL-10 stimulation. RESULTS: Forty-two subjects were enrolled in this study: 19 with CD and 23 controls. Stimulation of monocytes with LPS markedly increased IL-10R expression in both groups but to a much lower extent in patients with CD. In addition, IL-10-mediated suppression of TNFα production upon LPS stimulation and IL-10-induced STAT3 phosphorylation were attenuated in patients with CD versus controls. Finally, LPS-stimulated monocytes from patients with CD secreted significantly lower quantities of IL-10, compared with control monocytes. CONCLUSIONS:IL-10R expression and signaling are decreased in monocytes from patients with CD. Additional studies are required to assess whether similar patterns occur in other innate immune cells, especially in the gut, and whether disease activity, medical therapy, and genetic factors modulate these findings.
Authors: Dominik Aschenbrenner; Maria Quaranta; Stephen N Sansom; Holm H Uhlig; Soumya Banerjee; Nicholas Ilott; Joanneke Jansen; Boyd Steere; Yin-Huai Chen; Stephen Ho; Karen Cox; Carolina V Arancibia-Cárcamo; Mark Coles; Eamonn Gaffney; Simon Pl Travis; Lee Denson; Subra Kugathasan; Jochen Schmitz; Fiona Powrie Journal: Gut Date: 2020-10-09 Impact factor: 23.059
Authors: Stamatia Papoutsopoulou; Liam Pollock; Catherine Walker; William Tench; Sakim Shakh Samad; François Bergey; Luca Lenzi; Raheleh Sheibani-Tezerji; Phillip Rosenstiel; Mohammad Tauqeer Alam; Vitor A P Martins Dos Santos; Werner Müller; Barry J Campbell Journal: Front Immunol Date: 2021-06-16 Impact factor: 7.561
Authors: Pim J Koelink; Felicia M Bloemendaal; Bofeng Li; Liset Westera; Esther W M Vogels; Manon van Roest; Anouk K Gloudemans; Angelique B van 't Wout; Hannelie Korf; Séverine Vermeire; Anje A Te Velde; Cyriel Y Ponsioen; Geert Ram D'Haens; J Sjef Verbeek; Terrence L Geiger; Manon E Wildenberg; Gijs R van den Brink Journal: Gut Date: 2019-09-10 Impact factor: 23.059